Drugs / BIA 28-6156
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05220072 | Aug → Oct 2021 | Parkinson disease | Bial R&D Investments, S.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05819359 | Mar 2023 → Apr 2026 overdue | Parkinson disease | Bial R&D Investments, S.A. | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07522606 | — | Parkinson disease | Bial R&D Investments, S.A. | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-09 | Bial - Portela C S.A. | Results Bial Reports Topline Results from ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s bial.com ↗
BIA 28-6156 did not demonstrate significant differentiation from placebo on the primary or key secondary endpoints measured. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-09 | Bial - Portela C S.A. | Bial Reports Topline Results from ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s bial.com ↗ |
| 2026-05-26 | Bial - Portela C S.A. | Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s bial.com ↗ |
| 2025-10-02 | Bial - Portela C S.A. | Key Milestone in ACTIVATE Phase 2 Clinical Trial of BIA 28-6156 bial.com ↗ |
| 2025-01-07 | Bial - Portela C S.A. | Bial Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson’s Disease bial.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIA 28-6156 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07522606 ↗ |
| Known as | Carbon-14 BIA 28-6156 | “Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14” NCT05220072 ↗ |
| Route | Oral | “All subjects will receive a single oral dose Carbon-14 BIA 28-6156” NCT05220072 ↗ |